Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan PharmaCyte Biotech (PMCB)

PMCB (pharmacyte.com) - tandha merek perusahaan

PharmaCyte Biotech (PMCB) is exposed to risks stemming from global biomaterial supply chain disruptions and sanction restrictions. The quarterly earnings per share (EPS) growth rate demonstrates business resilience, with the metric reaching 56.20. Growth is driven by partnerships with oncology centers for cell encapsulation, while operations in the US provide stability and protection under humanitarian law.

pharmacyte.com (PMCB) - Wutah bathi EPS kuartalan saka 04.07.2022 nganti 10.11.2026

PharmaCyte Biotech (PMCB) - rincian metrik lan laporan keuangan

- nilai pasar lan prakiraan target analis:
Bagan rega pharmacyte.com|PMCB - Rata-rata rega prakiraan
- rincian kapitalisasi pasar:
Nilai pasar PharmaCyte|PMCB - Rega Nyata Tumbas Perusahaan Kanthi Wutuh
- data kapitalisasi buku:
Nilai Buku saben Saham PharmaCyte Biotech|PMCB - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku pharmacyte.com|PMCB - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal PharmaCyte Biotech|PMCB - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas pharmacyte.com|PMCB - Gunggung tanggungan utang perusahaan|Utang-utang marang kapitalisasi buku PharmaCyte|PMCB - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan PharmaCyte Biotech|Likuiditas cepet pharmacyte.com
- indikator bathi lan kelipatan valuasi:
PMCB - Bathi pungkasan|Bathi sing dikarepake PharmaCyte Biotech|PMCB - Koefisien rega marang bathi|Pangali Forward P/E pharmacyte.com|PMCB - Pangali PEG|Pangali EV/EBITDA PharmaCyte|PMCB - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan PharmaCyte Biotech|PMCB - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan pharmacyte.com|PMCB - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep PharmaCyte Biotech
Analisis umum perusahaan:PharmaCyte Biotech Inc. - PMCB
Barang unggulan pharmacyte.com

Investors must evaluate the fundamental quality and resilience of PharmaCyte Biotech (PMCB) through the dynamics of quarterly earnings per share. By analyzing the growth rate of quarterly EPS, one can identify hidden imbalances and stagnation risks, which for PharmaCyte Biotech (PMCB) depend directly on the reliability of external CMO contractors providing critical encapsulation processes and clinical trials.

Karo sapa PharmaCyte Biotech saingan

TriSalus Life Sciences, Inc. (TLSI) - Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan RenovoRx Inc (RNXT)